Roth Capital Weighs in on Revelation Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:REVB)

Revelation Biosciences, Inc. (NASDAQ:REVB) – Research analysts at Roth Capital lifted their Q3 2024 earnings estimates for shares of Revelation Biosciences in a note issued to investors on Tuesday, September 24th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($0.95) per share for the quarter, up from their prior estimate of ($1.59). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($12.46) per share. Roth Capital also issued estimates for Revelation Biosciences’ Q4 2024 earnings at ($0.59) EPS, FY2024 earnings at ($6.44) EPS, FY2025 earnings at ($3.95) EPS, FY2026 earnings at ($4.10) EPS, FY2027 earnings at ($2.48) EPS and FY2028 earnings at $2.30 EPS.

Revelation Biosciences (NASDAQ:REVB) last issued its quarterly earnings data on Friday, August 9th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.27.

Revelation Biosciences Price Performance

NASDAQ:REVB opened at $0.84 on Friday. The business’s 50-day simple moving average is $1.13 and its 200-day simple moving average is $1.80. Revelation Biosciences has a fifty-two week low of $0.70 and a fifty-two week high of $25.26. The stock has a market capitalization of $1.38 million, a PE ratio of -0.03 and a beta of 0.19.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.